Products for Research Use Only

Oditrasertib

CAT: 0804-HY-148787-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-148787-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Oditrasertib (SAR443820) is an orally active, BBB-penetrable and selective reversible inhibitor of RIPK1. Oditrasertib can be used in the research of chronic inflammatory central nervous system diseases, such as amyotrophic lateral sclerosis and multiple sclerosis[1][2][3].
CAS Number
2252271-93-3
Product Name Alternative
SAR443820; DNL788
UNSPSC
12352005
Target
RIP kinase
Type
Reference compound
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/oditrasertib.html
Purity
99.24
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
N#CC1=CN=CC2=C1OCCN(C2)C(C(C)(C(F)F)C)=O
Molecular Formula
C14H15F2N3O2
Molecular Weight
295.28
References & Citations
[1]Fidalgo JDV, et al. Preparation of substituted oxazepines and related compounds as RIPK1 inhibitors and uses thereof. WO2018213632A1. 2018-11-22. |[2]Hincelin-Mery A, et al. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clin Transl Sci. 2024 Jan;17 (1) :e13690. |[3]Montalban X, et al. Effect of RIPK1 inhibitor, SAR443820, on serum neurofilament light levels in patients with multiple sclerosis: a phase 2 trial design (P6-3.011) [J]. Neurology, 2023, 100 (17_supplement_2) : 2178.|[4]Hincelin-Mery A, et al. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clin Transl Sci. 2024 Jan;17 (1) :e13690.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
RIPK1

Alternative Products